58837-16-4

Basic information

• Product Name: 1,3,5-Triazine, hexahydro-1,3,5-tris[(4-methoxyphenyl)methyl]-
• CAS NO: 58837-16-4
• Molecular Formula: C27H33N3O3
• Molecular Weight: 447.577
• Mol File: 58837-16-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1,3,5-Triazine, hexahydro-1,3,5-tris[(4-methoxyphenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-Triazine, hexahydro-1,3,5-tris[(4-methoxyphenyl)methyl]-(58837-16-4)
• EPA Substance Registry System: 1,3,5-Triazine, hexahydro-1,3,5-tris[(4-methoxyphenyl)methyl]-(58837-16-4)

Safety Data

• Hazardous Substances Data: 58837-16-4(Hazardous Substances Data)

Usage

Appearance

White to off-white solid

Usage

Intermediate in the synthesis of various pharmaceuticals and organic compounds

Structure

Trisubstituted triazine with three 4-methoxybenzyl groups attached to the nitrogen atoms

Applications

a. Reagent in organic synthesis
b. Building block for the preparation of complex molecules
c. Potential applications in the development of new materials and drug discovery

Upstream product

• 50-00-0 formaldehyd 
• 824-94-2 p-methoxybenzyl chloride 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 2393-23-9 4-methoxy-benzylamine 
• 195005-12-0 N-[(diphenylphosphinoyl)methyl]-N-(4-methoxybenzyl)amine 
• 93591-40-3 (3S,4R)-3-<(R)-1-(t-butyldimethylsilyloxy)ethyl>-4-diethoxyphosphinyl-1-(4-methoxybenzyl)-2-azetidinone 
• 93591-34-5 (2S,3R)-N-(diethoxyphosphinylmethyl)-N-(4-methoxybenzyl)-2-bromo-3-hydroxybutyramide 
• 93591-36-7 (3S,4R)-4-diethoxyphosphinyl-3-<(R)-1-hydroxyethyl>-1-(4-methoxybenzyl)-2-azetidinone 
• 454-31-9 ethyl difluoroacetate 
• 93622-99-2 N-(diethoxyphosphinylmethyl)-4-methoxybenzylamine 

Relevant articles and documents

Facile Access to 3-Unsubstituted Tetrahydroisoquinolonic Acids via the Castagnoli-Cushman Reaction

Hitherto undescribed 3-unsubstituted tetrahydroisoquinolonic acids (isolated as their respective methyl esters) were accessed for the first time by the uncatalyzed, thermally promoted Castagnoli-Cushman reaction (CCR) of homophthalic anhydride (HPA) and a series of 1,3,5-triazinanes. The moderate yields observed in some cases are most likely associated with a persistent impurity also formed in these reactions. The new scaffold is expected to find novel medicinal utility (compared to the traditional CCR adducts) because it lacks a substituent at the 3-position.

Hydroheteroarylation of Unactivated Alkenes Using N-Methoxyheteroarenium Salts

We report the first reductive coupling of unactivated alkenes with N-methoxy pyridazinium, imidazolium, quinolinium, and isoquinolinium salts under hydrogen atom transfer (HAT) conditions, and an expanded scope for the coupling of alkenes with N-methoxy pyridinium salts. N-Methoxy pyridazinium, imidazolium, quinolinium, and isoquinolinium salts are accessible in 1-2 steps from the commercial arenes or arene N-oxides (25-99%). N-Methoxy imidazolium salts are accessible in three steps from commercial amines (50-85%). In total 36 discrete methoxyheteroarenium salts bearing electron-donating, electron-withdrawing, alkyl, aryl, halogen, and haloalkyl substituents were prepared (several in multigram quantities) and coupled with 38 different alkenes. The transformations proceed under neutral conditions at ambient temperature, provide monoalkylation products exclusively, and form a single alkene addition regioisomer. Preparatively useful and complementary site selectivities in the addition of secondary and tertiary radicals to pyidinium salts are documented: harder secondary radicals favor C-2 addition (2->10:1), while softer tertiary radicals favor bond formation to C-4 (4.7->29:1). A diene possessing a 1,2-disubstituted and 2,2-disubstituted alkene undergoes hydropyridylation at the latter exclusively (61%) suggesting useful site selectivities can be obtained in polyene substrates. The methoxypyridinium salts can also be employed in dehydrogenative arylation, borono-Minisci, and tandem arylation processes. Mechanistic studies support the involvement of a radical process.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.